SIRPA and neoplasm: Despite the increased affinity of NOD SIRPα to huCD47 compared to the human -human interaction, maplirpacept can still reduce tumor burden, suggesting that it successfully blocks the interaction between NOD muSIRPα and huCD47 and still triggers NOD macrophages to phagocytose human tumors.